Back to Search Start Over

Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation.

Authors :
Colonna L
Peterson CW
Schell JB
Carlson JM
Tkachev V
Brown M
Yu A
Reddy S
Obenza WM
Nelson V
Polacino PS
Mack H
Hu SL
Zeleski K
Hoffman M
Olvera J
Furlan SN
Zheng H
Taraseviciute A
Hunt DJ
Betz K
Lane JF
Vogel K
Hotchkiss CE
Moats C
Baldessari A
Murnane RD
English C
Astley CA
Wangari S
Agricola B
Ahrens J
Iwayama N
May A
Stensland L
Huang MW
Jerome KR
Kiem HP
Kean LS
Source :
Nature communications [Nat Commun] 2018 Oct 25; Vol. 9 (1), pp. 4438. Date of Electronic Publication: 2018 Oct 25.
Publication Year :
2018

Abstract

Allogeneic transplantation (allo-HCT) has led to the cure of HIV in one individual, raising the question of whether transplantation can eradicate the HIV reservoir. To test this, we here present a model of allo-HCT in SHIV-infected, cART-suppressed nonhuman primates. We infect rhesus macaques with SHIV-1157ipd3N4, suppress them with cART, then transplant them using MHC-haploidentical allogeneic donors during continuous cART. Transplant results in ~100% myeloid donor chimerism, and up to 100% T-cell chimerism. Between 9 and 47 days post-transplant, terminal analysis shows that while cell-associated SHIV DNA levels are reduced in the blood and in lymphoid organs post-transplant, the SHIV reservoir persists in multiple organs, including the brain. Sorting of donor-vs.-recipient cells reveals that this reservoir resides in recipient cells. Moreover, tetramer analysis indicates a lack of virus-specific donor immunity post-transplant during continuous cART. These results suggest that early post-transplant, allo-HCT is insufficient for recipient reservoir eradication despite high-level donor chimerism and GVHD.

Details

Language :
English
ISSN :
2041-1723
Volume :
9
Issue :
1
Database :
MEDLINE
Journal :
Nature communications
Publication Type :
Academic Journal
Accession number :
30361514
Full Text :
https://doi.org/10.1038/s41467-018-06736-7